6 Meridian’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

6 Meridian’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,157	Closed	-$349K	–	516
2021 Q2	$349K	Buy	8,157 +7	+0.1%	+$289	0.03%	214
2021 Q1	$340K	Buy	8,150 +1,798	+28%	+$83.5K	0.03%	216
2020 Q4	$296K	Buy	6,352 +155	+3%	+$7.25K	0.03%	213
2020 Q3	$263K	Buy	+6,197	New	+$271K	0.03%	210
2018 Q3	–	Sell	-2,946	Closed	-$223K	–	524
2018 Q2	$223K	Buy	+2,946	New	+$185K	0.02%	397

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

6 Meridian's EGRX Position: Q3 2021 in Review

6 Meridian sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2021, closing a stake of 8,157 shares — an estimated $349K sold.

6 Meridian first reported a position in EGRX in Q2 2018 and held it in 5 quarters. The position peaked at $349K in Q2 2021. 151 funds tracked by Wall St. Rank hold EGRX as of Q3 2021.

6 Meridian reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
6 Meridian sold 8,157 Eagle Pharmaceuticals, Inc. shares in Q3 2021, an estimated $349K.
6 Meridian first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2018 and held it in 5 quarters.
6 Meridian's Eagle Pharmaceuticals, Inc. position peaked at $349K in Q2 2021.
151 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2021.

Based on 6 Meridian's 13F filing for Q3 2021, filed 3 Nov 2021.